

# EFFICACY AND TOLERABILITY OF 3<sup>RD</sup> GENERATION FLUOROQUINOLONE FLOXIUM IN COMPARISON WITH ORIGINAL DRUG IN TREATMENT OF COPD EXACERBATION

***S. M. Polyvoda, O. V. Kulinich***

## *Summary*

There was conducted a clinical trial of efficacy of Floxium 500 mg tablets, produced by "Kievmedpreparat" (pharmaceutical corporation "Arterium"), in comparison with original drug Tavanik® 500 mg tablets, produced by "SanofiAventis", in treatment of COPD exacerbation. Clinical efficacy of Floxium was identical to efficacy of original drug. There were no difference of Floxium vs Tavanik® in terms of antibacterial effect (microbial spectrum, time to decrease or normalization of body temperature, influence on sputum properties, normalization of blood count). Absence of serious adverse events and unfavorable change of laboratory indices in patients confirm the safety of Floxium in 10 days treatment of COPD exacerbation.